The MolecuLight i:X was recently featured in a timely invited review article discussing the current challenges and future outlook in the management of diabetic foot . As many of us know, diabetic foot ulcers, are a serious health problem in our society today. People with diabetes have a 25% chance of developing a diabetic foot ulcer in their lifetime.
Among the various clinical wound assessment methods employed today, the following were discussed in the article published in the journal Diabetic Medicine: visualization of bacteria, temperature, oxygen saturation, skin perfusion and wearable technology as they relate to diabetic wound care.
The authors discuss that incorporating the MolecuLight i:X into wound care protocols may help address the ever-increasing battle against antibiotic resistance and supports an objective means toward improving antibiotic stewardship.
With the MolecuLight i:X, clinicians are given real-time visual information, at the point-of-care, to aid in the assessment and documentation of wounds . When combined with clinical best practice, fluorescence imaging of wounds offers clinicians real-time information on bacterial presence and distribution [1,2] .This can guide early interventions to reduce bioburden and promote wound healing while decreasing wound care costs associated with delayed wound healing and ineffective treatments [1,3].
For details about the article highlighting the MolecuLight i:X, see:
 DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, et al. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).
 Blumenthal E, Jeffrey S. The use of MolecuLight i:X in burn wounds. Proceedings of the Annual Australian & New Zealand Burn Association Conference; 2016 Oct 11-14; Auckland NZ.
 MolecuLight. Avoid unnecessary use of antimicrobial dressings with the MolecuLight i:X [Case study 0038]. 2016.